Journal of Comprehensive Pediatrics

Published by: Kowsar

Changing Management of Kawasaki Disease

Francesco Vierucci 1 , * , Andrea Azzarelli 2 , Rossana Gualtierotti 3 and Raffaele Domenici 1
Authors Information
1 Pediatric Unit, San Luca Hospital, Lucca, Italy
2 Cardiology Unit, San Luca Hospital, Lucca, Italy
3 Pediatric Unit, San Francesco Hospital, Barga, Italy
Article information
  • Journal of Comprehensive Pediatrics: August 01, 2014, 5 (3); e19519
  • Published Online: August 12, 2014
  • Article Type: Editorial
  • Received: June 23, 2014
  • Revised: June 23, 2014
  • Accepted: July 13, 2014
  • DOI: 10.17795/compreped-19519

To Cite: Vierucci F, Azzarelli A, Gualtierotti R, Domenici R. Changing Management of Kawasaki Disease, J Compr Ped. 2014 ; 5(3):e19519. doi: 10.17795/compreped-19519.

Copyright © 2014, Iranian Society of Pediatrics. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
  • 1. Newburger JW, Takahashi M, Gerber MA, Gewitz MH, Tani LY, Burns JC, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Pediatrics. 2004; 114(6): 1708-33[DOI][PubMed]
  • 2. Vierucci F, Tuoni C, Moscuzza F, Saggese G, Consolini R. Erythema multiforme as first sign of incomplete Kawasaki disease. Ital J Pediatr. 2013; 39: 11[DOI][PubMed]
  • 3. Eleftheriou D, Levin M, Shingadia D, Tulloh R, Klein NJ, Brogan PA. Management of Kawasaki disease. Arch Dis Child. 2014; 99(1): 74-83[DOI][PubMed]
  • 4. Sleeper LA, Minich LL, McCrindle BM, Li JS, Mason W, Colan SD, et al. Evaluation of Kawasaki disease risk-scoring systems for intravenous immunoglobulin resistance. J Pediatr. 2011; 158(5): 831-3[DOI][PubMed]
  • 5. Kobayashi T, Saji T, Otani T, Takeuchi K, Nakamura T, Arakawa H, et al. Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomised, open-label, blinded-endpoints trial. Lancet. 2012; 379(9826): 1613-20[DOI][PubMed]
  • 6. Chen S, Dong Y, Yin Y, Krucoff MW. Intravenous immunoglobulin plus corticosteroid to prevent coronary artery abnormalities in Kawasaki disease: a meta-analysis. Heart. 2013; 99(2): 76-82[DOI][PubMed]
  • 7. Choueiter NF, Olson AK, Shen DD, Portman MA. Prospective open-label trial of etanercept as adjunctive therapy for kawasaki disease. J Pediatr. 2010; 157(6): 960-966 e1[DOI][PubMed]
  • 8. Soleimani G, Sadeghi Bojd S, Tajik M, Shafighi Shahri E, Rashidi S. Paraclinical Evolutions Regarding Liver and Renal Abnormalities of Kawasaki Disease in the Southeast of Iran. J Compr Pediatrics. 2014; 5(1)
  • 9. Sedighi I, Biglari M, Olfat M, Yadolahi H, Tanasan A, Torabian S. Clinical characteristics and outcomes of Iranian patients with Kawasaki Disease. J Compr Pediatrics. 2014; 5(1)
  • 10. Taddio A, Pellegrin MC, Centenari C, Filippeschi IP, Ventura A, Maggiore G. Acute febrile cholestatic jaundice in children: keep in mind Kawasaki disease. J Pediatr Gastroenterol Nutr. 2012; 55(4): 380-3[DOI][PubMed]
  • 11. Yi DY, Kim JY, Choi EY, Choi JY, Yang HR. Hepatobiliary risk factors for clinical outcome of Kawasaki disease in children. BMC Pediatr. 2014; 14: 51[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments